Item type |
学術雑誌論文 / Journal Article(1) |
公開日 |
2020-10-26 |
タイトル |
|
|
言語 |
en |
|
タイトル |
Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease |
言語 |
|
|
言語 |
eng |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
non-alcoholic fatty liver disease |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
nonalcoholic steatohepatitis |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
pemafibrate |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
liver function |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
liver fibrosis |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
non-alcoholic fatty liver disease |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
nonalcoholic steatohepatitis |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
pemafibrate |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
liver function |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
liver fibrosis |
資源タイプ |
|
|
資源タイプ |
journal article |
著者 |
イケダ, スグル
スギハラ, タカアキ
ホシノ, ヨウヘイ
マツキ, ユカコ
ナガハラ, タカカズ
オカノ, ジュンイチ
キタオ, ソノコ
フジオカ, ヨウヘイ
ヤマモト, カズヒロ
イソモト, ハジメ
Ikeda, Suguru
Hoshino, Yoshiki
Matsuki, Yukako
Kitao, Sonoko
|
著者所属(英) |
|
|
|
en |
|
|
Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University |
著者所属(英) |
|
|
|
en |
|
|
Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University |
著者所属(英) |
|
|
|
en |
|
|
Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University |
著者所属(英) |
|
|
|
en |
|
|
Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University |
著者所属(英) |
|
|
|
en |
|
|
Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University |
著者所属(英) |
|
|
|
en |
|
|
Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University |
著者所属(英) |
|
|
|
en |
|
|
Division of Medicine and Clinical Science, Department of Cardiovascular Medicine and Endocrinology and Metabolism, School of Medicine, Faculty of Medicine, Tottori University |
著者所属(英) |
|
|
|
en |
|
|
Division of Medicine and Clinical Science, Department of Cardiovascular Medicine and Endocrinology and Metabolism, School of Medicine, Faculty of Medicine, Tottori University |
著者所属(英) |
|
|
|
en |
|
|
Division of Medicine and Clinical Science, Department of Cardiovascular Medicine and Endocrinology and Metabolism, School of Medicine, Faculty of Medicine, Tottori University |
著者所属(英) |
|
|
|
en |
|
|
Division of Medicine and Clinical Science, Department of Cardiovascular Medicine and Endocrinology and Metabolism, School of Medicine, Faculty of Medicine, Tottori University |
抄録 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
[Background] Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease related to metabolic syndrome, which can progress to liver cirrhosis. Standard medication has not been established. Pemafibrate is a selective peroxisome proliferatoractivated receptor (PPAR) α modulator. We retrospectively evaluated the efficacy of pemafibrate in patients with NAFLD. [Methods] We retrospectively enrolled 17 patients (ten men, seven women; median age, 63 years; range, 27?81 years). They were all proven to have fatty liver through imaging and had little or no history of drinking (ethanol consumption of < 20 g/day for women and < 30 g/day for men). They were administered pemafibrate from October 2018 to June 2020. [Results] After administration, serum triglyceride (TG) tended to be decreased (300.5 ± 22.5 to 239.5 ± 34.3 mg/dL, P = 0.06). Serum high-density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) cholesterol levels did not change. ALT was significantly decreased (-47.4%) for six months (57.5 ± 8.8 to 30.3 ± 5.8 U/L, P < 0.01). The values of serum GGT significantly decreased (-48.7%) for sixth months (63.9 ± 10.3 to 32.8 ± 6.6 U/L, P < 0.01). Aspartate aminotransferase (AST) to platelet ratio (APRI), a fibrosis marker, also was significantly decreased in the sixth month (0.7 ± 0.1 to 0.4 ± 0.1, P < 0.05). Body mass index (BMI) and hemoglobin A1c (HbA1c) showed no significant change. [Conclusion] Pemafibrate dramatically ameliorated the values of liver function tests and APRI in patients with NAFLD. |
書誌情報 |
Yonago Acta Medica
en : Yonago Acta Medica
巻 63,
号 3,
p. 188-197,
発行日 2020-08-20
|
雑誌内区分 |
|
|
|
Original Article |
出版者 |
|
|
出版者 |
Tottori University Medical Press |
ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
05135710 |
書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA00892882 |
DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.33160/yam.2020.08.009 |
権利 |
|
|
権利情報 |
Yonago Acta medica 編集委員会 |
情報源 |
|
|
|
関連名称 |
Ikeda Suguru, Sugihara Takaaki, Hoshino Yoshiki,et al. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. Yonago Acta Medica. 2020, 63(3). 188-197. doi: 10.33160/ |
関連サイト |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://www.jstage.jst.go.jp/article/yam/63/3/63_2020.08.009/_article/ |
|
|
関連名称 |
https://www.jstage.jst.go.jp/article/yam/63/3/63_2020.08.009/_article/ |
関連サイト |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
http://www.lib.tottori-u.ac.jp/yam/yam/yam63-3/63-3contents.html |
|
|
関連名称 |
http://www.lib.tottori-u.ac.jp/yam/yam/yam63-3/63-3contents.html |
著者版フラグ |
|
|
出版タイプ |
VoR |
EISSN |
|
|
|
1346-8049 |